New clotting drug put to the test: how long does it last?

NCT ID NCT06579144

Recruiting now Knowledge-focused Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study looks at how long a new drug for severe hemophilia A stays active in the body compared to two existing drugs. About 24 adult men will receive a single dose of their current drug, then later a single dose of the new drug. The goal is to measure and compare the drugs' half-life and safety, not to provide treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sobi Investigational Site
RECRUITING

Sofia, Bulgaria

Contact
Sobi Investigational Site
RECRUITING

Bonn, Germany

Contact
Sobi Investigational Site
RECRUITING

Milan, Italy

Contact
Sobi Investigational Site
NOT_YET_RECRUITING

Naples, Italy

Contact
Sobi Investigational Site
RECRUITING

A Coruña, Spain

Contact
Sobi Investigational Site
RECRUITING

Valencia, Spain

Contact
Sobi Investigational Site
RECRUITING

Zaragoza, Spain

Contact
Sobi Investigational site
RECRUITING

Frankfurt, Germany

Contact

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA A